

Cirevetmab Biosimilar - Research Grade

Product Code: ICH5440

More Information

Species Reactivity: Human

Target: TGFB1

Concentration: 5mg/ml

Isotype: IgG2 - kappa

Host: CHO Cells

product name H2: Cirevetmab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P01137

Shipping Conditions: Blue ice

background: Transforming growth factor beta 1 (TGF-beta 1) is a master regulator of fibrosis, immune suppression and tissue remodeling, studied broadly across cancer and fibrosis research. Offered as an unconjugated, non-therapeutic analog of cirevetmab, this human IgG2-kappa recombinant antibody is intended for research use only (RUO). It is provided low in endotoxin to in vivo standards and produced in scalable milligram-to-gram quantities for bulk and high-throughput laboratories. The antibody supports functional and neutralization assays, TGF-beta signaling studies, in vitro screening and preclinical fibrosis and tumor-microenvironment models.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE



Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks